학술논문
Safety and activity of the first-in-class locked nucleic acid (LNA) miR-221 selective inhibitor in refractory advanced cancer patients: a first-in-human, phase 1, open-label, dose-escalation study
Document Type
Article
Author
Tassone, P.; Di Martino, M.T.; Cordua, A.; Scionti, F.; Lopreiato, M.; Cuomo, O.; Riillo, C.; Caracciolo, D.; Tagliaferri, P.; Arbitrio, M.; Fiorillo, L.; Staropoli, N.; Ciliberto, D.; Salvino, A.; Gualtieri, S.; Barbieri, V.; Bertucci, B.; Manti, F.; Thunarf, F.; Zito, M.C.; De Fina, M.R.; Brescia, A.; Di Francesco, A.E.; Di Paola, E.D.
Source
In: Journal of Hematology and Oncology . (Journal of Hematology and Oncology, December 2023, 16(1))
Subject
Language
English
ISSN
17568722